SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

DIL hits upper circuit on plan to sign term sheet to acquire stake in its subsidiary

12 Oct 2017 Evaluate

DIL is currently trading at its upper circuit limit of Rs. 1045.10, up by 49.75 points or 5.00% from its previous closing of Rs. 995.35 on the BSE.

The scrip opened at Rs. 1045.10 and has touched a high and low of Rs. 1045.10 and Rs. 1045.10 respectively.

The BSE group 'XT' stock of face value Rs. 10 has touched a 52 week high of Rs. 1070.00 on 11-Oct-2017 and a 52 week low of Rs. 590.00 on 04-Sep-2017.

Last one week high and low of the scrip stood at Rs. 1070.00 and Rs. 748.00 respectively. The current market cap of the company is Rs. 239.66 crore.

The promoters holding in the company stood at 62.59%, while institutions and non-institutions held 0.01% and 37.40% respectively.

DIL has received an approval to sign a Term Sheet to acquire 3,830,072 equity shares in its subsidiary, Fermenta Biotech (FBL), representing 21.05% of the issued and paid-up capital of FBL, from Evolvence India Life Sciences Fund LLC, a Private Equity Investor. The Board of Directors of the company at its meeting held on October 11, 2017 have authorised the same.

DIL (earlier known as Duphar-Interfran) is a well-respected public listed company. It has built a stellar reputation for itself in the arenas of pharmaceuticals, biotechnology, environmental solutions and other segments including Entertainment and Health & Wellness.

Fermenta Biotech Share Price

312.55 -9.30 (-2.89%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×